A Phase 2a, Multicenter, Single Arm, Open Label, Two Stage, Study To Evaluate The Efficacy, Safety, Tolerability And Pharmacokinetics Of Pf 06480605 In Subjects With Moderate To Severe Ulcerative Colitis

Trial Profile

A Phase 2a, Multicenter, Single Arm, Open Label, Two Stage, Study To Evaluate The Efficacy, Safety, Tolerability And Pharmacokinetics Of Pf 06480605 In Subjects With Moderate To Severe Ulcerative Colitis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Dec 2017

At a glance

  • Drugs PF 6480605 (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 09 Aug 2017 Planned End Date changed from 1 Nov 2018 to 27 Nov 2018.
    • 09 Aug 2017 Planned primary completion date changed from 1 Sep 2018 to 4 Sep 2018.
    • 20 Jul 2017 Planned primary completion date changed from 20 Nov 2018 to 1 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top